MCID: THY029
MIFTS: 62

Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Thyroid Carcinoma

MalaCards integrated aliases for Thyroid Carcinoma:

Name: Thyroid Carcinoma 59 29 55 6 17
Thyroid Cancer 37 29 55 43

Characteristics:

Orphanet epidemiological data:

59
thyroid carcinoma
Prevalence: 6-9/10000 (Europe),1-5/10000 (United States),1-9/100000 (Worldwide),1-5/10000 (Worldwide); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

KEGG 37 H00032
UMLS via Orphanet 73 C0549473
Orphanet 59 ORPHA100088

Summaries for Thyroid Carcinoma

MedlinePlus : 43 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It makes hormones that help the body work normally. There are several types of cancer of the thyroid gland. You are at greater risk if you Are between ages 25 and 65 Are a woman Are Asian Have a family member who has had thyroid disease Have had radiation treatments to your head or neck You should see a doctor if you have a lump or swelling in your neck. Doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. Treatment depends on the type of cancer you have and how far the cancer has spread. Many patients receive a combination of treatments. They may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Thyroid Carcinoma, also known as thyroid cancer, is related to thyroid carcinoma, familial medullary and thyroid cancer, nonmedullary, 1, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Thyroid Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid cancer and Transcriptional misregulation in cancer. The drugs Betamethasone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are Decreased viability and Decreased viability

KEGG : 37
Thyroid cancer is the most common endocrine malignancy and accounts for the majority of endocrine cancer- related deaths each year. More than 95% of thyroid carcinomas are derived from follicular cells. Their behavior varies from the indolent growing, well-differentiated papillary and follicular carcinomas (PTC and FTC, respectively) to the extremely aggressive undifferentiated carcinoma (UC). Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages. The most distinctive molecular features of FTC are the prominence of aneuploidy and the high prevalence of RAS mutations and PAX8-PPAR{gamma} rearrangements. p53 seems to play a crucial role in the dedifferentiation process of thyroid carcinoma.

Related Diseases for Thyroid Carcinoma

Diseases related to Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1090)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, familial medullary 35.0 TG RET NTRK1 NKX2-1 CALCA
2 thyroid cancer, nonmedullary, 1 34.0 PTCSC3 NKX2-1 NEAT1 BRAF
3 differentiated thyroid carcinoma 33.2 TSHR TPO TG RET PCM1 NTRK1
4 thyroiditis 31.7 TSHR TPO TG RET CALCA
5 hyperthyroidism 31.6 TSHR TPO TG
6 thyroid cancer, nonmedullary, 2 31.5 TSHR TPO TG RET PTEN PIK3CA
7 graves disease 1 31.5 TSHR TPO TG
8 ovarian germ cell teratoma 31.3 TG RET NKX2-1
9 papillary thyroid microcarcinoma 31.3 TSHR TG NKX2-1 CALCA BRAF
10 struma ovarii 31.3 TSHR TG RET NKX2-1 BRAF
11 hypothyroidism 31.2 TSHR TPO TG RET NKX2-1 CALCA
12 endemic goiter 31.1 TSHR TPO TG
13 goiter 31.0 TSHR TPO TG NKX2-1 LGALS3 CALCA
14 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 TSHR TPO TG
15 testicular germ cell tumor 30.9 PTEN HRAS BRAF
16 multinodular goiter 30.9 TSHR TPO TG NKX2-1 HRAS CALCA
17 suppurative thyroiditis 30.9 TG CALCA
18 parathyroid carcinoma 30.8 RET LGALS3 CALCA
19 nodular goiter 30.7 TSHR TPO TG RET LGALS3 CALCA
20 adenocarcinoma 30.7 RET PTEN PIK3CA HRAS CDH1 BRAF
21 ovarian germ cell cancer 30.7 TG RET NKX2-1
22 small cell carcinoma 30.7 PTEN NKX2-1 CALCA
23 melanoma, cutaneous malignant 1 30.7 PTEN PIK3CA HRAS BRAF
24 benign struma ovarii 30.7 TSHR TG RET HRAS
25 subacute thyroiditis 30.7 TSHR TPO TG
26 toxic diffuse goiter 30.6 TSHR TPO TG
27 endocrine gland cancer 30.6 TG RET PTEN HRAS CDH1 CALCA
28 renal cell carcinoma, papillary, 1 30.6 PTEN PIK3CA HRAS BRAF
29 goiter, multinodular 1, with or without sertoli-leydig cell tumors 30.6 TPO TG
30 subacute lymphocytic thyroiditis 30.5 TPO TG
31 papillary carcinoma 30.5 TSHR TPO TG RET NKX2-1 LGALS3
32 congenital hypothyroidism 30.5 TSHR TPO TG NKX2-1
33 colonic disease 30.5 RET HRAS CDH1
34 familial thyroid dyshormonogenesis 30.5 TPO TG
35 athyreosis 30.4 TSHR TG NKX2-1
36 squamous cell carcinoma, head and neck 30.4 PTEN PIK3CA HRAS CDH1 BRAF
37 malignant struma ovarii 30.4 TG RET NKX2-1 LGALS3 HRAS
38 colloid adenoma 30.4 TG NKX2-1 LGALS3
39 ovarian cystic teratoma 30.4 TG NKX2-1 CALCA
40 hashimoto thyroiditis 30.4 TSHR TPO TG RET LGALS3 CALCA
41 carcinosarcoma 30.4 PTEN PIK3CA HRAS
42 myxedema 30.3 TSHR TPO TG
43 adenoid cystic carcinoma 30.3 PTEN PIK3CA HRAS CDH1
44 nontoxic goiter 30.3 TSHR TPO TG CALCA
45 spitz nevus 30.3 HRAS BRAF
46 hemangioma 30.3 RET PTEN NKX2-1
47 ovarian serous cystadenocarcinoma 30.3 PIK3CA HRAS BRAF
48 small cell cancer of the lung 30.3 PTEN PIK3CA NKX2-1 CALCA
49 thyroid gland disease 30.3 TSHR TPO TG RET NKX2-1 LGALS3
50 follicular adenoma 30.3 TSHR TPO TG RET PTEN NKX2-1

Graphical network of the top 20 diseases related to Thyroid Carcinoma:



Diseases related to Thyroid Carcinoma

Symptoms & Phenotypes for Thyroid Carcinoma

UMLS symptoms related to Thyroid Carcinoma:


tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.98 HRAS PIK3CA BRAF
2 Decreased viability GR00221-A-1 9.98 AXL CDH1 HRAS PIK3CA RET
3 Decreased viability GR00221-A-2 9.98 AXL HRAS PIK3CA RET
4 Decreased viability GR00221-A-3 9.98 HRAS NTRK1
5 Decreased viability GR00221-A-4 9.98 AXL PIK3CA RET BRAF
6 Decreased viability GR00231-A 9.98 RET
7 Decreased viability GR00301-A 9.98 AXL CDH1 RET BRAF NTRK1
8 Decreased viability GR00381-A-1 9.98 BRAF
9 Decreased viability GR00402-S-2 9.98 AXL CDH1 HRAS PIK3CA RET BRAF
10 Decreased substrate adherent cell growth GR00193-A-1 9.43 AXL
11 Decreased substrate adherent cell growth GR00193-A-3 9.43 AXL BRAF
12 Decreased substrate adherent cell growth GR00193-A-4 9.43 AXL BRAF NTRK1

MGI Mouse Phenotypes related to Thyroid Carcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 BRAF CDH1 HRAS LGALS3 NKX2-1 NTRK1
2 homeostasis/metabolism MP:0005376 10.29 AXL BRAF CDH1 HRAS LGALS3 NKX2-1
3 endocrine/exocrine gland MP:0005379 10.26 AXL BRAF CDH1 HRAS NKX2-1 PIK3CA
4 cardiovascular system MP:0005385 10.25 AXL BRAF CDH1 HRAS LGALS3 NKX2-1
5 immune system MP:0005387 10.2 AXL BRAF CDH1 LGALS3 NTRK1 PIK3CA
6 hematopoietic system MP:0005397 10.19 AXL BRAF LGALS3 NTRK1 PTEN RET
7 mortality/aging MP:0010768 10.18 AXL BRAF CDH1 HRAS LGALS3 NKX2-1
8 digestive/alimentary MP:0005381 10.14 BRAF CDH1 HRAS LGALS3 NKX2-1 PTEN
9 integument MP:0010771 10.03 AXL BRAF CDH1 HRAS LGALS3 NTRK1
10 nervous system MP:0003631 10.03 AXL BRAF HRAS LGALS3 NKX2-1 NTRK1
11 neoplasm MP:0002006 9.97 BRAF CDH1 HRAS LGALS3 NKX2-1 PIK3CA
12 limbs/digits/tail MP:0005371 9.95 BRAF NTRK1 PTEN RET TG TPO
13 reproductive system MP:0005389 9.81 AXL BRAF CDH1 LGALS3 NKX2-1 PIK3CA
14 skeleton MP:0005390 9.65 AXL BRAF HRAS LGALS3 NKX2-1 PIK3CA
15 vision/eye MP:0005391 9.23 AXL BRAF NTRK1 PIK3CA PTEN SDC4

Drugs & Therapeutics for Thyroid Carcinoma

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Doxorubicin Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. DB00997
2 Iodide I-131 Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. DB09293

Drugs for Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 351)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Codeine Approved, Illicit Phase 4 76-57-3 5284371
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
7
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
8 Anti-Asthmatic Agents Phase 4
9 Betamethasone-17,21-dipropionate Phase 4
10 Betamethasone Valerate Phase 4 2152-44-5
11 Betamethasone sodium phosphate Phase 4
12 Betamethasone acetate Phase 4
13 Betamethasone benzoate Phase 4
14 Analgesics Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Peripheral Nervous System Agents Phase 4
17 Central Nervous System Depressants Phase 4
18 Respiratory System Agents Phase 4
19 Narcotics Phase 4
20 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
21 Analgesics, Opioid Phase 4
22 Antipyretics Phase 4
23 Antitussive Agents Phase 4
24
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
25
Glucagon Approved Phase 3 16941-32-5
26
Cinacalcet Approved Phase 3 226256-56-0 156419
27
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
28 Fluorodeoxyglucose F18 Phase 2, Phase 3
29 Radiopharmaceuticals Phase 2, Phase 3
30 Gastrointestinal Agents Phase 3
31 Calcium, Dietary Phase 3
32 Fibrin Tissue Adhesive Phase 3
33 Coagulants Phase 3
34 Glucagon-Like Peptide 1 Phase 3
35 Calcimimetic Agents Phase 3
36 insulin Phase 3
37 Insulin, Globin Zinc Phase 3
38
Apatinib Phase 3 811803-05-1
39
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
40
leucovorin Approved Phase 2 58-05-9 143 6006
41
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
42
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
43
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
46
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
47
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
48
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
49
Fluorouracil Approved Phase 2 51-21-8 3385
50
Hydroxyurea Approved Phase 2 127-07-1 3657

Interventional clinical trials:

(show top 50) (show all 562)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
3 Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
4 A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal Completed NCT00001730 Phase 4 Thyrogen
5 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
6 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
7 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
8 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
9 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
10 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT02946918 Phase 4 Levothyroxine
11 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Not yet recruiting NCT03969108 Phase 4 Indocyanine Green
12 Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter Withdrawn NCT02329379 Phase 4 Levothyroxine
13 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
14 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
15 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
16 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
17 A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer Completed NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
18 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
19 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
20 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
21 Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections Completed NCT01126060 Phase 3 Usage of Fibrin sealant
22 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
23 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
24 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
25 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
26 A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
27 Cinacalcet Actions in Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
28 A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
29 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed NCT01722266 Phase 3 Liraglutide;Placebo
30 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
31 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
32 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Recruiting NCT01149161 Phase 2, Phase 3
33 A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
34 A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
35 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
36 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
37 Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
38 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032) Active, not recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
39 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00704730 Phase 3 XL184;Placebo
40 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
41 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China Active, not recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
42 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
43 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
44 Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq Active, not recruiting NCT00115895 Phase 3 Radioactive iodine
45 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
46 A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
47 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
48 Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
49 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
50 Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake Unknown status NCT01396733 Phase 2 alpha-lipoic acids

Search NIH Clinical Center for Thyroid Carcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Doxorubicin
Iodide I-131

Genetic Tests for Thyroid Carcinoma

Genetic tests related to Thyroid Carcinoma:

# Genetic test Affiliating Genes
1 Thyroid Cancer 29
2 Thyroid Carcinoma 29

Anatomical Context for Thyroid Carcinoma

MalaCards organs/tissues related to Thyroid Carcinoma:

41
Thyroid, Lymph Node, Bone, Breast, Testes, Lung, Brain

Publications for Thyroid Carcinoma

Articles related to Thyroid Carcinoma:

(show top 50) (show all 34654)
# Title Authors PMID Year
1
Serum thyroglobulin elevation after needle aspiration of the lymph nodes: the predictive value for detecting metastasis in papillary thyroid cancer patients - a pilot study. 38 17
31374007 2019
2
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report. 38 17
31374006 2019
3
Occult papillary thyroid cancer presenting as cystic metastasis of the lateral neck: A case report. 38 17
31348321 2019
4
INSL3 has tumor-promoting activity in thyroid cancer. 9 38
19950223 2010
5
The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. 9 38
20200941 2010
6
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. 9 38
19898969 2010
7
Diagnostic utility of galectin-3 in thyroid cancer. 9 38
20363921 2010
8
Relaxin enhances S100A4 and promotes growth of human thyroid carcinoma cell xenografts. 9 38
20332215 2010
9
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. 9 38
19913280 2010
10
Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? 9 38
20017617 2010
11
[Usefulness of the determination of thyroglobulin in lymph node aspirates of patients with papillary thyroid carcinoma and positive antithyroglobulin antibodies]. 9 38
20096208 2009
12
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. 9 38
19878585 2009
13
Molecularly targeted therapies for thyroid cancers. 9 38
19546052 2009
14
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. 9 38
19524134 2009
15
Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. 9 38
19652218 2009
16
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. 9 38
19480010 2009
17
New targets and therapeutic approaches for endocrine malignancies. 9 38
19374919 2009
18
Multiple neoplasia in a 15-year-old girl with familial adenomatous polyposis. 9 38
19564752 2009
19
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 9 38
19506552 2009
20
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. 9 38
19173293 2009
21
Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. 9 38
19499990 2009
22
[Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma]. 9 38
19771906 2009
23
Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer. 9 38
19493000 2009
24
How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. 9 38
19147628 2009
25
Sporadic medullary thyroid carcinoma: clinical data from a university hospital. 9 38
19488601 2009
26
Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. 9 38
19199318 2009
27
Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. 9 38
19156774 2009
28
Lysosomal acid hydrolases of the cathepsin family are novel targets of INSL3 in human thyroid carcinoma cells. 9 38
19416220 2009
29
HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas. 9 38
19060921 2009
30
Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. 9 38
19589101 2009
31
Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. 9 38
19160311 2009
32
Evaluation of a new method for the diagnosis of alterations of Lens culinaris agglutinin binding of thyroglobulin molecules in thyroid carcinoma. 9 38
19743952 2009
33
TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. 9 38
19047914 2009
34
Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. 9 38
18657294 2008
35
Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. 9 38
18571834 2008
36
Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. 9 38
18682709 2008
37
Multifocal hyperfunctioning thyroid carcinoma without metastases. 9 38
17826928 2008
38
Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: a population based case-control study in China. 9 38
18783589 2008
39
CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. 9 38
18757431 2008
40
Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. 9 38
18758416 2008
41
Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment. 9 38
18284635 2008
42
Can calcitonin and carcinoembryonic antigen doubling times predict progression of thyroid carcinoma? 9 38
18542112 2008
43
Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. 9 38
18528186 2008
44
Expression and distribution of S-100, CD83 and apoptosis-related proteins (Fas, FasL and Bcl-2) in tissues of thyroid carcinoma. 9 38
18840555 2008
45
Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. 9 38
18630997 2008
46
[Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma]. 9 38
18682151 2008
47
Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. 9 38
18630998 2008
48
Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. 9 38
18098308 2008
49
Expression of thyroid transcription factor-1 in brain metastases: a useful indicator of pulmonary origin. 9 38
18413286 2008
50
Regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by DJ-1 in thyroid cancer cells. 9 38
18430896 2008

Variations for Thyroid Carcinoma

ClinVar genetic disease variations for Thyroid Carcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 RET NM_020630.5(RET): c.1900T> C (p.Cys634Arg) single nucleotide variant Pathogenic rs75076352 10:43609948-43609948 10:43114500-43114500

Expression for Thyroid Carcinoma

Search GEO for disease gene expression data for Thyroid Carcinoma.

Pathways for Thyroid Carcinoma

Pathways related to Thyroid Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Thyroid cancer hsa05216
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 PTEN PIK3CA NTRK1 HRAS BRAF
2
Show member pathways
12.68 PTEN PIK3CA HRAS CDH1 BRAF
3
Show member pathways
12.64 PIK3CA NTRK1 HRAS CDH1 BRAF
4
Show member pathways
12.55 RET PTEN PIK3CA NTRK1 HRAS CDH1
5
Show member pathways
12.51 PTEN PIK3CA HRAS CDH1 BRAF AXL
6
Show member pathways
12.51 PTEN PIK3CA NTRK1 HRAS CDH1 BRAF
7 12.42 RET PTEN PIK3CA NTRK1 HRAS CDH1
8
Show member pathways
12.39 SDC4 PTEN PIK3CA HRAS BRAF
9
Show member pathways
12.32 SDC4 PIK3CA HRAS BRAF
10
Show member pathways
12.32 PTEN PIK3CA HRAS BRAF
11
Show member pathways
12.23 PIK3CA NTRK1 HRAS CDH1 BRAF AXL
12 12.2 SDC4 PIK3CA HRAS BRAF
13
Show member pathways
12.06 PTEN PIK3CA NTRK1 HRAS BRAF
14 12.04 PTEN PIK3CA NTRK1 HRAS
15
Show member pathways
11.99 PTEN PIK3CA HRAS BRAF
16 11.84 PTEN HRAS BRAF
17 11.66 HRAS CDH1 BRAF
18 11.6 PTEN PIK3CA HRAS
19
Show member pathways
11.59 RET PIK3CA HRAS BRAF
20 11.48 PTEN PIK3CA HRAS
21 11.46 TSHR PIK3CA HRAS BRAF
22 11.31 PIK3CA NTRK1 HRAS BRAF
23 11.3 RET PIK3CA HRAS
24 11.29 RET PIK3CA HRAS
25 11.18 PIK3CA HRAS CDH1
26 11.15 PTEN PIK3CA HRAS
27 10.86 RET PTEN PIK3CA NTRK1 HRAS
28 10.22 RET PIK3CA HRAS
29 9.91 TSHR TPO TG

GO Terms for Thyroid Carcinoma

Cellular components related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.93 TSHR TPO SDC4 RET PTEN PIK3CA
2 receptor complex GO:0043235 9.26 TSHR RET NTRK1 AXL
3 cell surface GO:0009986 9.17 TSHR TPO SDC4 NTRK1 LGALS3 CDH1

Biological processes related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 RET PTEN NKX2-1 HRAS BRAF
2 protein phosphorylation GO:0006468 9.91 RET PIK3CA NTRK1 CALCA BRAF AXL
3 negative regulation of apoptotic process GO:0043066 9.86 PTEN NTRK1 BRAF AXL
4 axon guidance GO:0007411 9.83 RET PIK3CA NTRK1 NKX2-1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.76 RET NTRK1 BRAF AXL
6 protein kinase B signaling GO:0043491 9.58 PTEN PIK3CA AXL
7 negative regulation of neuron apoptotic process GO:0043524 9.55 PIK3CA NTRK1 HRAS BRAF AXL
8 hormone biosynthetic process GO:0042446 9.54 TPO TG
9 positive regulation of MAPK cascade GO:0043410 9.54 RET NTRK1 HRAS
10 endothelial cell migration GO:0043542 9.5 PTEN PIK3CA CALCA
11 regulation of axon regeneration GO:0048679 9.49 PTEN BRAF
12 myeloid progenitor cell differentiation GO:0002318 9.48 MLF1 BRAF
13 thyroid gland development GO:0030878 9.43 TG NKX2-1 BRAF
14 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.26 PTEN NTRK1 HRAS BRAF
15 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.25 NTRK1
16 cellular response to nerve growth factor stimulus GO:1990090 8.8 PTEN NTRK1 BRAF
17 cell differentiation GO:0030154 10.04 RET NTRK1 MLF1 LGALS3 BRAF AXL

Molecular functions related to Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 RET NTRK1 AXL
2 protein tyrosine kinase activity GO:0004713 8.92 RET NTRK1 BRAF AXL

Sources for Thyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....